NCT05579782 · REGISTRY CONDITION SEARCH

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: NA
Status at capture: COMPLETED
Registry last update: 2025-07-31

This study describes a single center, randomized, single-blinded clinical trial to assess the clinical benefits of the use of near infrared autofluorescence (NIRAF) detection with an FDA-cleared device 'Parathyroid Eye (PTeye)' for identifying parathyroid glands during total thyroidectomy. It compares risk-benefits and outcomes in patients undergoing total thyroidectomy where NIRAF detection with PTeye for parathyroid identification is either used or not used.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Subjects With Transient Hypoparathyroidism.

→

outcome · POSTED

Patients With Hypoparathyroidism at Last Follow-up

→

outcome · POSTED

Overall Average Number of Parathyroid Glands Identified With High Confidence.

→

outcome · POSTED

Number of Participants With Frozen Sections Sent for Analysis.

→

outcome · POSTED

Number of Participants With Auto-transplanted Parathyroid Glands

→

outcome · POSTED

Number of Participants Who Spent Nights in the Hospital After Total Thyroidectomy

→

outcome · POSTED

Number of Participants With Inadvertently Resected Parathyroid Glands

→

outcome · POSTED

Number of Doctor Visits/Emergency Department Visits or Hospital Admissions

→

outcome · POSTED

Duration and Total Daily Dosage of Calcium and/or Vitamin D Supplementation After Surgery

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: (i) All patients eligible for total thyroidectomy (TTx), with or without lymph node dissection. (includes patients undergoing a TTx who have undergone a prior neck exploration for parathyroid disease or other but have an intact thyroid). (ii) All patients undergoing completion thyroidectomy. Exclusion Criteria: (i) Patients with concurrent parathyroid disease. (ii) Patients with incidental enlarged parathyroid discovered during TTx. (iii) Patients undergoing thyroid lobectomy/partial thyroidectomy.
healthy Volunteers: true
maximum Age: 99 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
intervention Names
Device: NIRAF Detection Technology
label
NIRAF Detection Technology (+)
type
EXPERIMENTAL
description
Parathyroid gland identification will be performed by the surgeon using only visual identification and without using PTeye - NIRAF detection technology in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
label
NIRAF Detection Technology (-)
type
NO_INTERVENTION

interventions

arm Group Labels
NIRAF Detection Technology (+)
description
Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device). After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid. Other Name: PTeye Device
name
NIRAF Detection Technology
type
DEVICE

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

intervention Model Description

NIRAF detection technology is used as an adjunctive tool for intraoperative parathyroid identification in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND) in the interventional group. Generic Name of Device: Parathyroid Autofluorescence Detection Device (NIRAF detection technology). The Parathyroid Autofluorescence Detection Device consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nanometer (nm) laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 Milliwatts (mW). The device has an FDA clearance for clinical use in general surgeries and dermatological use (Class 2 device).

masking Info

masking: SINGLE
masking Description: Only participants will be masked to the intervention.
who Masked: PARTICIPANT

primary Purpose

PREVENTION

Enrollment

count: 80
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The number of subjects with hypoparathyroidism. For the transient hypoparathyroidism; the definition utilized was a serum parathyroid hormone (PTH) level \<10 pg/mL.
measure
Subjects With Transient Hypoparathyroidism.
time Frame
24-48 hours post-op
description
The number of subjects with hypoparathyroidism at last follow-up. Follow-up defined as PTH less than the normal institutional range.
measure
Patients With Hypoparathyroidism at Last Follow-up
time Frame
2 days to 1 year after surgery

secondary Outcomes

description
Overall number of parathyroid glands identified (Experimental Group: Glands identified with naked eye + NIRAF; Control Group: Glands identified with naked eye)
measure
Overall Average Number of Parathyroid Glands Identified With High Confidence.
time Frame
Immediate (during total thyroidectomy, up to 3 hours)
description
Number of participants with frozen sections sent for analysis during the procedure to confirm potential parathyroid tissue.
measure
Number of Participants With Frozen Sections Sent for Analysis.
time Frame
Immediate (during total thyroidectomy, up to 3 hours)
description
Number of participants with auto-transplanted parathyroid glands if the parathyroid gland was accidentally excised/devascularized.
measure
Number of Participants With Auto-transplanted Parathyroid Glands
time Frame
Immediate (during total thyroidectomy, up to 3 hours)
description
Number of participants who spent nights for postoperative recovery in the hospital after the surgical procedure.
measure
Number of Participants Who Spent Nights in the Hospital After Total Thyroidectomy
time Frame
0-72 hours after total thyroidectomy
description
Number of participants with inadvertently resected parathyroid glands when parathyroid tissue is found in the resected thyroid specimens.
measure
Number of Participants With Inadvertently Resected Parathyroid Glands
time Frame
Immediate (intraoperative) to 7-10 days after total thyroidectomy (pathology report)
description
Number of doctor visits/emergency department visits or hospital admissions due to hypocalcemia and or associated symptoms.
measure
Number of Doctor Visits/Emergency Department Visits or Hospital Admissions
time Frame
Up to 6 months after total thyroidectomy
description
Duration and total daily dosage of calcium and/or vitamin D supplementation after surgery - if patient had no prior history of supplementation.
measure
Duration and Total Daily Dosage of Calcium and/or Vitamin D Supplementation After Surgery
time Frame
Up to 6 months after total thyroidectomy

Full study description

brief Summary: This study describes a single center, randomized, single-blinded clinical trial to assess the clinical benefits of the use of near infrared autofluorescence (NIRAF) detection with an FDA-cleared device 'Parathyroid Eye (PTeye)' for identifying parathyroid glands during total thyroidectomy. It compares risk-benefits and outcomes in patients undergoing total thyroidectomy where NIRAF detection with PTeye for parathyroid identification is either used or not used.
detailed Description: Inadvertent damage or excision of a healthy parathyroid gland (PG) following a total thyroidectomy (TTx) could result in transient hypocalcemia (\< 6 months) in 5 - 35% of cases or permanent hypocalcemia (\> 6 months) in 7% of the patients (1, 2). In both of these circumstances, patients would require calcium and active vitamin D supplementation in addition to a potentially prolonged hospital stay and/or unplanned hospital readmission adding to unnecessary burden and healthcare costs. These complications could be minimized with label-free intraoperative PG identification using near infrared autofluorescence (NIRAF) detection with a fiber-probe based approach as utilized in 'PTeye', which is medical device that was recently FDA-cleared. However, the true impact of this particular NIRAF-based approach on patient outcomes is yet to be determined The aim of this prospective single blinded randomized study is to compare 2 groups of patients: TTx patients operated using NIRAF detection technology with PTeye as adjunct tool (NIRAF+) vs. patients operated without the adjunct technology (NIRAF-). The main objective of this study is to assess the benefit of intraoperative use of NIRAF detection technology via PTeye during TTx procedures with regard to postoperative hypocalcemia, PG identification, PG auto-transplantation and inadvertent resection rates compared to standard of care.

Source references

references

citation
Cousart AG, Kiernan CM, Willmon PA, Thomas G, Wang TS, Gauger PG, Duh QY, Underwood HJ, Jackson A, Patel A, Mahadevan-Jansen A, Solorzano CC. Near-Infrared Autofluorescence for Parathyroid Detection During Endocrine Neck Surgery: A Randomized Clinical Trial. JAMA Surg. 2025 Sep 1;160(9):936-944. doi: 10.1001/jamasurg.2025.2233.
pmid
40668552
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f7e571b9f9b8d654f2df
requested nct id
NCT05579782
primary nct id
NCT05579782
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Parathyroid+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2b4988b513f0b70e7c49c0c10cabf5241c1231b8e29e89b78dc9406bd8749c8a
payload sha256
117517ff0687c1430475b8e293d92f08d27883b4807a64942dc6e4f40257d3e7
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f7e571b9f9b8d654f2df
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT05579782
occurrences
context exact
NCT05579782
end
11
exact text
NCT05579782
start
0
offset unit
unicode_code_points
query cond
Parathyroid Cancer
query disease state id
ds-parathyroid-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-parathyroid-cancer-000.json
source file sha256
2b4988b513f0b70e7c49c0c10cabf5241c1231b8e29e89b78dc9406bd8749c8a
source json pointer
/studies/18/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c6fe3e2dfddf26e0901e030ad55f6087d0d16e9d4ce459331796381cbea12572
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Parathyroid+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice